Genmab Lands $1.1B Cancer Deal with 'Perfect Partner' J&J
LONDON – Genmab A/S signed up a "dream partner" for its anti-CD38 monoclonal antibody daratumumab, agreeing a worldwide commercialization deal with Janssen Biotech Inc., with a total potential value of more than $1.1 billion, of which $135 million is to be paid up front.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST